AC
RXRX icon

Allstate Corporation’s Recursion Pharmaceuticals RXRX Stock Holding History

Allstate Corporation’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$469K Buy
+127,713
New +$425K ﹤0.01% 1057

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Allstate Corporation's RXRX Position: Q2 2026 in Review

Allstate Corporation opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 127,713 shares worth $469K. The stake represents ﹤0.01% of the portfolio and ranks #1057 among its holdings.

342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

  • Allstate Corporation held 127,713 shares of Recursion Pharmaceuticals worth $469K as of Q2 2026.
  • Recursion Pharmaceuticals was a new Allstate Corporation position in Q2 2026.
  • Recursion Pharmaceuticals made up ﹤0.01% of Allstate Corporation's portfolio in Q2 2026, its #1057 holding.
  • 342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Allstate Corporation's 13F filing for Q2 2026, filed 13 Aug 2026.